Abstract Short-chain acyl-CoA dehydrogenase (ACAD) deficiency is an extremely rare inherited mitochondrial disorder of fat metabolism. This belongs to a group of diseases known as fatty acid oxidation disorders. Screening programmes have provided evidence that all the fatty acid oxidation disorders combined are among the most common inborn errors of metabolism. Mitochondrial beta oxidation of fatty acids is an essential energy producing pathway. It is a particularly important pathway during prolonged periods of starvation and during periods of reduced caloric intake due to gastrointestinal illness or increased energy expenditure during febrile illness. The most common presentation is an acute episode of life threatening coma and hypoglycemia induced by a period of fasting due to defective hepatic ketogenesis. Here, the case of a 4 month old female patient who had seizures since the third day of her birth and persistent hypoglycemia is described. She was born to parents of second degree consanguinity after 10 years of infertility treatment. There was history of delayed cry after birth. Metabolic screening for TSH, galactosemia, 17-OHP, G6PD, cystic fibrosis, biotinidase were normal. Tandem mass spectrometric (TMS) screening for blood amino acids, organic acids, fatty acids showed elevated butyryl carnitine (C4) as 3.40 lmol/L (normal \2.00 lmol/L), hexanoyl carnitine (C6) as 0.92 lmol/L (normal \0.72 lmol/L), C4/C3 as 2.93 lmol/L (normal \1.18 lmol/L). The child was started immediately on carnitor syrup (carnitine) 1/2 ml twice daily. Limitation of fasting stress and dietary fat was advised. Baby responded well by gaining weight and seizures were controlled. Until now, less than 25 patients have been reported worldwide. The limited number of patients diagnosed until now is due to the rarity of the disorder resulting in under diagnosis.
Introduction
Mitochondrial enzyme deficiencies comprise an important group of potentially fatal, incurable human diseases that primarily affect children. These include mitochondrial enzyme deficiencies that are involved in catabolism of amino acids, fatty acids and other intermediary metabolites. One sub group of these disorders is the fatty acid beta oxidation defects, notably the acyl-CoA dehydrogenase (ACAD) deficiencies [1] .
Mitochondrial fatty acid oxidation results in sequential cleavage of 2 carbon units from fatty acids and represents an important source of energy for the body during the time of fasting and metabolic stress. It also serves as a continuous source of energy for the heart. Energy production after release of free fatty acids from adipose tissue is a complicated process that occurs in four basic stages: the carnitine cycle; beta-oxidation; the electron transfer pathway; and in the liver, the synthesis of ketone bodies. The ACAD are adehydrogenation of the acyl-CoA esters, transferring electrons to electron transferring flavoprotein (ETF). In humans, very long, medium and short chain ACAD (VLAD, MCAD, and SCAD) catalyze the first step in the beta-oxidation cycle with substrate optima of 16, 8 and 4 carbon chains, respectively (Fig. 1) .
SCAD (E.C. 1.3.99.2) deficiency is an inherited autosomal recessive disorder which was first reported in 1987. Since then, approximately 25 patients have been identified and 50 reported worldwide based upon reduced or absent SCAD activity in vitro [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Genotype-phenotype correlations have been inconsistent [8, 18] . It is a heterogeneous disorder in which the clinical phenotype varies from fatal metabolic decompensation in infancy with failure to thrive, developmental delay, hypotonia, seizures [5] , sudden infant death syndrome (SID), progressive myopathy to asymptomatic individuals [10] . All patients with documented SCAD deficiency secrete increased concentration of ethylmalonic acid in their urine. This originates from the accumulation of butyryl-CoA which is a substrate for SCAD [19] . Occasionally increased methyl succinic acid and butyrylglycine are noted in the urine [20] . Plasma acyl carnitine examination may show an increase of butyryl carnitine (C4)-carnitine (butyrylcarnitine).
Case Report
A 4 month old female was the first child of related parents (second degree consanguinity) born after 10 years of infertility treatment. Pregnancy was uneventful and she was delivered spontaneously with a birth weight of 3,250 g. Head circumference was 35 cm and crown rump length was 52 cm. There was history of delayed cry after birth. The patient had seizures since the third day of her birth. Neither neck holding nor social smile were present at the end of 4 months. She had persistent hypoglycemia (55 mg%) and hypotonia.
Brain CT and MRI, CSF examination, abdominal ultrasonography and chromosomal analysis were normal. The patient was referred to our department at the end of 4 months of age. Physical examination showed mild development delay. Blood glucose levels were 55 mg%. Ketone bodies in the blood were absent. EEG showed changes for generalized seizures. Metabolic screening for TSH, galactosemia, 17 OHP, G6PD, biotinidase, blood ammonia were normal. Urinary amino acid profile showed slightly elevated levels of glycine and lysine.
Organic acid levels in the urine showed elevated ethyl malonic acid. TMS (Tandem mass spectrometry) screening for fatty acids showed elevated C4 as 3.40 lmol/L (nor-
The child was started immediately on carnitor syrup (carnitine) 1/2 ml twice daily. Limitation of prolonged fasting (1/2 h feed) and dietary fat was advised. Baby responded well by gaining weight and seizures were controlled. Blood glucose levels were maintained in the normal range. Early new born screening (NBS) could have led to early diagnosis and early treatment to prevent the grievous consequences. 
Methods
Clinical laboratory investigations performed on the patient included glucose (enzymatic test kit, Trinder's GOD-POD method kit, Transasia Biomedicals Limited, Daman, India), ammonia (Modified Fuji-okuda method, Wako Pure Chemical Industries Limited, Osaka, Japan), lactate (Enzymatic test kit, ETM Bioscience Inc, USA), ketone Bodies Enzymatic test kit, Abcam, UK). Metabolic screening for TSH, galactosemia, 17 OHP, G6PD, biotinidase (Neonatal ELISA kit, BIO-RAD Laboratories Europe Limited, Perth, UK). Carnitine and acyl carnitine profile by TMS; SCIEX API-365, Perkin-Elmer) in blood. Organic acid analysis in urine was performed by gas chromatography-mass spectrometry (GC-MSD, HP 6890, Hewlett-Packard).
Discussion and Conclusion
This patient presented with developmental delay, seizures, hypotonia and hypoglycemia (55 mg%). Ethyl malonic acid levels in the urine were elevated. On two occasions of hypoglycemia elevated levels of C4, C6, C4/C3 were reported. These biochemical findings confirmed the diagnosis of SCAD deficiency.
Till date, 25 patients have been identified and 50 reported worldwide based upon reduced or absent SCAD activity in vitro [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Genotype-phenotype correlations have been inconsistent [8, 18] . It is a heterogenous disorder in which the clinical phenotype varies from fatal metabolic decompensation in infancy with failure to thrive, developmental delay, hypotonia, seizures, progressive myopathy, to asymptomatic individuals [9] . This study will furnish better insights on the phenotypic variation of the disease with less number of clinical, biochemical and genetically proved cases available. More cases need to be studied before a realistic picture of phenotypic variation is obtained in SCAD deficiency. The possibility of diagnosis and symptomatic therapy suggest that defects in fatty acid beta-oxidation may be suspected in all patients with neurological problems like developmental delay, seizures and hypotonia.
Fatty acid oxidation defects provide a classic example of how patients can derive great benefit from early detection. Prior to NBS, approximately 25% of known MCADD (medium chain acyl-CoA deficiency) patients died and another 30-40% of cases exhibited variable developmental delay [21] . By this, the morbidity and mortality is clearly significant.
In contrast, patients identified before the onset of symptoms and managed with appropriate preventive urgent care service have little morbidity and rare mortality with significant cost benefit to the health care system [22] .
Most symptomatic cases of SCAD deficiency have come to light due to large diagnostic work-up on children with non-specific findings such as developmental delay, failure to thrive and myopathy. Moreover, continued uncertainty over long term consequences of SCAD deficiency, can only be addressed by larger collaborative studies of individuals prior to symptoms.
In this regard, SCAD deficiency could prove to be a valuable model to study other metabolic diseases that are identified coincidentally with a technology TMS used in NBS. Continuing efforts to follow outcomes in such disorders and elucidate possible underlying mechanisms of disease will ultimately prove to be invaluable in guiding both NBS protocols as well as clinical management for physicians and families. In summary by NBS early diagnosis and early treatment is possible to prevent the long term complications.
Therefore, we describe another case of SCAD deficiency with typical clinical symptoms, indicating that a thorough workup of all cases with neurological symptoms like developmental delay, seizures and hypotonia is required. This will ensure that such cases cannot be missed out. The fact that SCAD deficiency is a rare metabolic disorder should not be a cause for under diagnosis.
